Can You Stay on a Low Dose of Wegovy? What the Label Allows, What Each Dose Delivers, and When Staying Low Makes Sense

Written by Diana Gangan. Updated October 28, 2026.

Yes, you can stay on a low dose of Wegovy, and since the 2025 label update it is not even off-label: 1.7 mg is now listed as a maintenance dose alongside 2.4 mg, and the label says to pick between them on response and tolerability. Below 1.7 mg is a different matter. The 0.25, 0.5 and 1 mg steps were designed as a four-week ramp, not as destinations, and the trials show why: at 1 mg people with diabetes lost about 7% of their body weight against 9.6% on 2.4 mg, and nobody has tested 0.5 mg as a long-term dose for weight at all. The low-dose question therefore has three honest answers depending on which dose you mean, and this guide gives all three, with the trial numbers for every step of the injection and every strength of the pill, the situations where staying low is the right call, what you give up, and how to have the conversation with your prescriber.

Wegovy's dosing schedule is four escalation doses of four weeks each, then maintenance. The current prescribing information lists the maintenance dose for weight reduction as 'either 1.7 mg or 2.4 mg (recommended) once weekly', with the choice guided by response and tolerability, and it lists the same two options for the cardiovascular-risk indication. For people on 2.4 mg who are not tolerating it, the dose can be decreased to 1.7 mg. The label also now allows going the other way: people who tolerate 2.4 mg for at least four weeks and need more weight loss can escalate to 7.2 mg, the high dose approved in 2026 after the STEP UP trial. The starting doses, 0.25 and 0.5 mg, are described as escalation steps 'to reduce the risk of gastrointestinal adverse reactions'; 1 mg is the third step. The full ladder and the missed-dose rules are in the Wegovy dosing schedule.

The best dose-response data for semaglutide come from the phase 2 trial that preceded Wegovy, in which 957 adults with obesity took daily injections for a year. Weight loss rose with dose: 6.0% at 0.05 mg a day, 8.6% at 0.1 mg, 11.6% at 0.2 mg and 13.8% at 0.4 mg, against 2.3% on placebo. Daily 0.1 mg is roughly equivalent to 0.7 mg a week and daily 0.2 mg to about 1.4 mg a week, so the trial says, in effect, that a weekly dose between 0.5 and 1 mg produces a bit over half the full effect, and a dose around 1.7 mg produces most of it. The phase 3 STEP 2 trial confirms the middle of that curve in people with diabetes: 7.0% on 1 mg, 9.6% on 2.4 mg. Two things follow. First, every dose works to some degree; the curve does not fall off a cliff below 2.4 mg. Second, the step from 1 mg to 2.4 mg buys roughly a quarter to a third more weight loss, which for a 100 kg person is another 3 to 5 kg. Whether that is worth the extra nausea is the whole low-dose decision, and what the full-dose trials delivered is in how much weight you can lose on Wegovy.

Since December 2025 Wegovy also comes as a daily tablet, with 1.5, 4 and 9 mg strengths for the first 90 days and 25 mg as the maintenance dose. The pattern is the same as the injection: the lower strengths are stepping stones. In the OASIS 4 trial, 25 mg produced 13.6% weight loss at 64 weeks against 2.2% on placebo; the 9 mg and 14 mg oral strengths were tested in diabetes trials and produced less weight loss. If 25 mg is not tolerated, the label does not list a lower oral maintenance dose; it says to consider switching to the 1.7 mg injection. One practical point in favour of the pill for low-dose maintenance is price: the NovoCare cash price is $149 a month for the lower strengths against $349 for any injection dose. The two forms are compared in Wegovy pill vs injection.

Staying on a lower dose is not a failure, and prescribers do it every week. The five situations below are the ones with a sound rationale.

Side-effect management at any dose, and the rare reactions that should stop the drug regardless of dose, are on our Wegovy side effects page.

Weight on semaglutide follows the dose with a lag of a few weeks. Drop from 2.4 mg to 1.7 mg and most people see appetite return slightly and weight plateau rather than rise; drop to 1 mg and some regain begins in a minority. Stop entirely and the STEP 1 extension study showed people regained about two-thirds of their lost weight within a year. The useful way to think about it is that each dose has its own equilibrium weight, and lowering the dose moves you toward the equilibrium of the new dose, which is higher than the old one but far below where you started. A lower dose is therefore a legitimate maintenance strategy for people who accept a few kilograms of drift in exchange for fewer side effects or lower cost; it is not a way to keep the full-dose result for free. The rebound data are in what happens when you stop Wegovy.

Wegovy's cardiovascular indication, a 20% reduction in heart attacks, strokes and cardiovascular death in people with established heart disease, was proven in the SELECT trial at 2.4 mg. The label extends the indication to 1.7 mg as a maintenance option, on the reasoning that the benefit tracks exposure and most of the exposure is present at 1.7 mg. It does not extend it to 1 mg or below, and no outcomes trial has tested those doses for that purpose. For someone taking Wegovy primarily for heart protection, 1.7 mg is the floor.

Most US plans that cover Wegovy approve it by indication, not by dose, so a prescription at 1.7 mg is filled the same way as 2.4 mg, and the four-pen box costs the plan and you the same either way. Two wrinkles exist. Some plans require documentation that you have titrated to 2.4 mg before they renew beyond the first six months, on the logic that they are paying for the full effect; a prescriber's note that 1.7 mg is the tolerated maintenance dose per label usually satisfies this. And some plans will cover Ozempic 1 mg for a person with type 2 diabetes who would not qualify for Wegovy, which is why some low-dose patients are technically on Ozempic. The savings card and the $349 NovoCare price apply at every dose. Coverage rules are in does insurance cover Wegovy and prices in Wegovy cost and savings.

The conversation goes better with numbers. Bring your weight trend over the last eight weeks, a note of which side effects you have and how many days a week they occur, and a clear goal: holding your current weight, losing a further amount, or getting the side effects down to tolerable. Then ask the specific question: 'Can we hold at 1.7 mg and review in three months?' or 'I am at goal; can we try 1 mg and see if I hold?' Prescribers are far more likely to agree to a defined trial with a review date than to an open-ended 'I want to stay low'. If the problem is slow loss rather than side effects, the fixes in five practical ways to boost weight loss on Wegovy and the timeline in how long Wegovy takes to work are worth reading before asking to change dose, because the answer is often time, not milligrams.

You can stay on a low dose of Wegovy, and at 1.7 mg the label says so explicitly. At 1 mg you are off-label but on solid trial ground, with about three-quarters of the full-dose effect. Below that, nobody has studied it, the effect is likely half or less, and the label calls those doses a ramp. The right dose is the lowest one that holds the weight you want with side effects you can live with, and the only way to find it is a defined trial with your prescriber and a scale. People who are not losing weight on Wegovy at any dose have a different problem, covered separately.

This article summarizes the Wegovy label and published trials for general information. Dose changes should be made only with your prescriber.